ACC: Expanding Eligibility for Low-Income Subsidies Can Improve CVD Medication Adherence

Medically reviewed by Carmen Pope, BPharm. Last updated on April 1, 2026.

via HealthDay

WEDNESDAY, April 1, 2026 -- Expanding eligibility for full low-income subsidies (LIS) to include those with incomes between 135 and 150 percent of the federal poverty level (FPL) is associated with a reduction in cost-related medication nonadherence in Medicare beneficiaries with cardiovascular disease or major cardiovascular risk factors. The research was published online March 24 in the Journal of the American College of Cardiology to coincide with the annual meeting of the American College of Cardiology, held from March 28 to 30 in New Orleans.

Lucas X. Marinacci, M.D., from the Beth Israel Deaconess Medical Center in Boston, and colleagues used National Health Interview Survey data from 2021 to 2024 to examine the impact of expanding full LIS eligibility among Medicare beneficiaries aged 65 years and older with one or more cardiovascular risk factors or conditions who reported taking one or more prescription medications in the past year. Medicare beneficiaries who became newly eligible under the Inflation Reduction Act (IRA; intervention group), which took effect in January 2024, were compared to beneficiaries with incomes ≤135 percent FPL already eligible for full subsidies (control group).

The study population included 28,010 Medicare beneficiaries with cardiovascular risk factors and conditions. The researchers found that compared with controls, there was a 5.5 percentage point reduction in cost-related medication nonadherence among Medicare beneficiaries who became newly eligible for full LIS after implementation of the 2024 IRA reforms. Findings were similar in direction and magnitude in analyses excluding beneficiaries with diabetes, although estimates were no longer statistically significant.

"Cardiology providers should continue asking Medicare patients about cost barriers and connecting them to financial counselors who can help them understand their drug coverage and take advantage of these reforms," Marinacci said in a statement.

Abstract/Full Text (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords